Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides (2015)
Sequence: Stearoyl-AGYLLGKLLOOLAAAALOOLL
PMO (phosphorodiamidate morpholino oligonucleotide; splice-switching)
| Experiment Id | EXP001002 |
|---|---|
| Paper | Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides |
| Peptide | PF14 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Formulated as nanoparticles; SMA fibroblast exon 7 inclusion (GM03813); dose-response across PMO lengths |
| Rna Concentration | PMO 175–700 nM and 0.5–1 µM (length-dependent) |
| Mixing Ratio | peptide:PMO molar ratio 5:1; tested 175–700 nM (23/25-mer) and 0.5–1 µM (18–25-mer) |
| Formulation Format | noncovalent lipopeptide/PMO nanoparticles (co-incubation; complex formation) |
| Formulation Components | PF14 + PMO SMA 18-mer (ISS-N1); 5'-TCACTTTCATAATGCTGG-3'; PMO SMA 20-mer (ISS-N1); 5'-ATTCACTTTCATAATGCTGG-3'; PMO SMA 23-mer (ISS-N1); 5'-ATTCACTTTCATAATGCTGGCAG-3'; PMO SMA 25-mer (ISS-N1); 5'-AGATTCACTTTCATAATGCTGGCAG-3' |
| Size Nm | 134.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U2OS stable luciferase reporter (BTK intron XLA model); SMA type I fibroblasts GM03813; H2K mdx myotubes + healthy H2K myotubes |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro splice switching (RT-PCR exon inclusion/skipping; luc reporter splice correction) |
| Output Value | Robust exon 7 inclusion even at 175 nM (23/25-mer); near-complete inclusion at higher doses. |
| Output Units | |
| Output Notes | Longer PMOs showed slightly higher splice-switching activity vs 18/20-mer in these assays. |
| Toxicity Notes | Myotube viability (MTS): no toxicity at working concentration (~5 µM peptide). St-RXR4 showed toxicity at 40 µM (without PMO). |
| Curation Notes |